Total Payments
$58,536
2022 Payments
$39.23
Companies
50
Transactions
498
Medicare Patients
737
Medicare Billing
$84,231
Payment Breakdown by Category
Other$29,979 (51.2%)
Research$10,000 (17.1%)
Food & Beverage$8,178 (14.0%)
Consulting$5,938 (10.1%)
Travel$3,869 (6.6%)
Education$572.55 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $29,979 | 20 | 51.2% |
| Unspecified | $10,000 | 6 | 17.1% |
| Food and Beverage | $8,178 | 440 | 14.0% |
| Consulting Fee | $5,938 | 2 | 10.1% |
| Travel and Lodging | $3,869 | 19 | 6.6% |
| Education | $572.55 | 11 | 1.0% |
Payments by Type
General
$48,536
492 transactions
Research
$10,000
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Avanir Pharmaceuticals, Inc. | $31,601 | 57 | $0 (2020) |
| ACADIA Pharmaceuticals Inc | $10,230 | 23 | $0 (2020) |
| Octapharma USA, Inc. | $5,654 | 8 | $0 (2017) |
| ABBVIE INC. | $2,856 | 27 | $0 (2022) |
| InSightec,Inc | $976.48 | 2 | $0 (2018) |
| UCB, Inc. | $741.17 | 84 | $0 (2020) |
| Teva Pharmaceuticals USA, Inc. | $663.92 | 13 | $0 (2019) |
| LivaNova USA, Inc. | $560.28 | 4 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $356.84 | 16 | $0 (2020) |
| EMD Serono, Inc. | $355.66 | 20 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $39.23 | 2 | ABBVIE INC. ($39.23) |
| 2021 | $13.03 | 1 | AbbVie Inc. ($13.03) |
| 2020 | $5,284 | 17 | ACADIA Pharmaceuticals Inc ($5,014) |
| 2019 | $12,279 | 130 | Avanir Pharmaceuticals, Inc. ($5,459) |
| 2018 | $21,163 | 150 | Avanir Pharmaceuticals, Inc. ($17,286) |
| 2017 | $19,758 | 198 | Avanir Pharmaceuticals, Inc. ($8,832) |
All Payment Transactions
498 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/03/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: HYPERHYDROSIS | ||||||
| 06/01/2022 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: HYPERHYDROSIS | ||||||
| 07/09/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.03 | General |
| Category: NEUROSCIENCE | ||||||
| 08/19/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: ACA 16-cAC-0001 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/16/2020 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: Neurology | ||||||
| 03/12/2020 | Alexion Pharmaceuticals, Inc. | Soliris (Drug) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Immunology | ||||||
| 03/06/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.29 | General |
| Category: NEUROSCIENCE | ||||||
| 02/18/2020 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $11.61 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 02/13/2020 | Acorda Therapeutics, Inc | INBRIJA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $16.25 | General |
| Category: PARKINSONS DISEASE | ||||||
| 02/04/2020 | Allergan, Inc. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $22.12 | General |
| Category: HYPERHYDROSIS | ||||||
| 02/03/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | — | Cash or cash equivalent | $2,000.00 | Research |
| Study: ACA 16-cAC-0001 • Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 01/29/2020 | SK Life Science, Inc. | — | Food and Beverage | In-kind items and services | $13.10 | General |
| 01/21/2020 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $16.33 | General |
| Category: NEUROLOGY | ||||||
| 01/16/2020 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 01/15/2020 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: CNS | ||||||
| 01/14/2020 | Novartis Pharmaceuticals Corporation | AIMOVIG (Biological) | Food and Beverage | In-kind items and services | $12.60 | General |
| Category: NEUROSCIENCE | ||||||
| 01/14/2020 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug) | Food and Beverage | In-kind items and services | $12.48 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 01/10/2020 | Vertical Pharmaceuticals, LLC | RELEXXII (Drug), LORZONE | Food and Beverage | In-kind items and services | $21.30 | General |
| Category: ADHD | ||||||
| 01/10/2020 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $12.53 | General |
| Category: Neurology | ||||||
| 01/08/2020 | Boston Scientific Corporation | GENERAL - DBS (Device) | Food and Beverage | In-kind items and services | $68.09 | General |
| Category: DBS | ||||||
| 12/24/2019 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $8.65 | General |
| Category: Neurology | ||||||
| 12/20/2019 | Merz North America, Inc. | XEOMIN (Biological) | Food and Beverage | Cash or cash equivalent | $0.48 | General |
| Category: MUSCULOSKELETAL | ||||||
| 12/19/2019 | Merz North America, Inc. | XEOMIN (Biological) | Food and Beverage | Cash or cash equivalent | $23.10 | General |
| Category: MUSCULOSKELETAL | ||||||
| 12/18/2019 | Genentech USA, Inc. | OCREVUS (Biological) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: Immunology | ||||||
| 12/18/2019 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $9.66 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ACA 16-cAC-0001 | ACADIA Pharmaceuticals Inc | $10,000 | 6 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 68 | 81 | $14,500 | $5,850 |
| 2022 | 3 | 76 | 100 | $15,431 | $6,144 |
| 2021 | 5 | 164 | 227 | $41,598 | $15,775 |
| 2020 | 14 | 429 | 3,706 | $317,570 | $56,463 |
Total Patients
737
Total Services
4,114
Medicare Billing
$84,231
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 27 | 27 | $7,093 | $2,644 | 37.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 37 | $4,364 | $2,149 | 49.2% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 17 | 17 | $3,043 | $1,057 | 34.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 34 | 52 | $6,386 | $2,442 | 38.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 28 | $4,959 | $2,158 | 43.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 20 | 20 | $4,086 | $1,544 | 37.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 67 | 112 | $14,222 | $5,971 | 42.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 43 | 61 | $11,816 | $4,653 | 39.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 22 | 22 | $9,668 | $3,375 | 34.9% |
| 99221 | Initial hospital inpatient care, typically 30 minutes per day | Facility | 2021 | 17 | 17 | $4,702 | $1,338 | 28.5% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 15 | 15 | $1,190 | $437.47 | 36.8% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 12 | 3,250 | $52,163 | $15,677 | 30.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 108 | 116 | $21,273 | $6,956 | 32.7% |
| 70553 | Mri scan of brain before and after contrast | Office | 2020 | 25 | 26 | $68,224 | $5,870 | 8.6% |
| 70551 | Mri scan brain | Office | 2020 | 30 | 30 | $44,670 | $4,356 | 9.8% |
| 72148 | Mri scan of lower spinal canal | Office | 2020 | 29 | 29 | $45,501 | $4,152 | 9.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 25 | 25 | $8,791 | $3,923 | 44.6% |
| 72141 | Mri scan of upper spinal canal | Office | 2020 | 26 | 26 | $40,612 | $3,527 | 8.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 72 | 74 | $8,954 | $2,876 | 32.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 28 | 49 | $6,842 | $2,761 | 40.3% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 22 | 22 | $6,578 | $1,891 | 28.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 16 | 19 | $3,953 | $1,542 | 39.0% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $4,312 | $1,136 | 26.3% |
| 95874 | Needle measurement and recording of electrical activity of muscles for guidance with injection of chemical for destruction of muscles | Office | 2020 | 14 | 18 | $2,826 | $1,007 | 35.6% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 11 | 11 | $2,871 | $789.91 | 27.5% |
About Dr. Thomas Banas, M.D
Dr. Thomas Banas, M.D is a Neurology healthcare provider based in Fort Wayne, Indiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1508863051.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Banas, M.D has received a total of $58,536 in payments from pharmaceutical and medical device companies, with $39.23 received in 2022. These payments were reported across 498 transactions from 50 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($29,979).
As a Medicare-enrolled provider, Banas has provided services to 737 Medicare beneficiaries, totaling 4,114 services with total Medicare billing of $84,231. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology
- Location Fort Wayne, IN
- Active Since 06/30/2005
- Last Updated 10/23/2023
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1508863051
Products in Payments
- NUEDEXTA (Drug) $27,440
- NUPLAZID (Drug) $10,230
- OCTAGAM (Biological) $5,654
- ONZETRA Xsail (Drug) $4,161
- Duopa (Drug) $2,748
- VNS Therapy (Device) $689.65
- Briviact (Drug) $546.44
- TROKENDI XR (Drug) $331.05
- XEOMIN (Biological) $280.42
- Rebif (Biological) $273.12
- ACTIVA (Device) $257.77
- OCREVUS (Biological) $245.21
- GILENYA (Drug) $234.49
- BOTOX (Biological) $218.86
- APTIOM (Drug) $217.30
- INGREZZA (Drug) $214.20
- AUSTEDO (Drug) $204.61
- ACTHAR (Biological) $185.49
- Fycompa (Drug) $178.13
- Vimpat (Drug) $172.04
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Fort Wayne
Atiya Khan, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Ajay Gupta, Md, MD
Neurology — Payments: $526,136
Neurology $526,136
Dr. Marlene Bultemeyer, Md, MD
Neurology — Payments: $250,320
Neurology $250,320
Paul Later, M.d, M.D
Neurology — Payments: $117,049
Neurology $117,049
Christopher Vachon
Neurology — Payments: $16,813
Neurology $16,813
Madhav Bhat, Md, MD
Neurology — Payments: $9,819
Neurology $9,819